HU223067B1 - Eljárás tramadol racemáthasítására - Google Patents
Eljárás tramadol racemáthasítására Download PDFInfo
- Publication number
- HU223067B1 HU223067B1 HU9700141A HUP9700141A HU223067B1 HU 223067 B1 HU223067 B1 HU 223067B1 HU 9700141 A HU9700141 A HU 9700141A HU P9700141 A HUP9700141 A HU P9700141A HU 223067 B1 HU223067 B1 HU 223067B1
- Authority
- HU
- Hungary
- Prior art keywords
- tramadol
- tartaric acid
- base
- enantiomer
- salt
- Prior art date
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 36
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims abstract description 31
- 229960004380 tramadol Drugs 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000003287 optical effect Effects 0.000 title description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 25
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000001358 L(+)-tartaric acid Substances 0.000 claims abstract description 14
- 235000011002 L(+)-tartaric acid Nutrition 0.000 claims abstract description 14
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims abstract description 14
- 239000012452 mother liquor Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 4
- 239000011975 tartaric acid Substances 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 229940095064 tartrate Drugs 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000006073 displacement reaction Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000002585 base Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PPKXEPBICJTCRU-UHFFFAOYSA-N [2-hydroxy-2-(3-methoxyphenyl)cyclohexyl]methyl-dimethylazanium;chloride Chemical compound Cl.COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000005051 trimethylchlorosilane Substances 0.000 description 3
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 229960003107 tramadol hydrochloride Drugs 0.000 description 2
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 description 1
- PPKXEPBICJTCRU-KUARMEPBSA-N (S,S)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-KUARMEPBSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- TVYLLZQTGLZFBW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Chemical compound COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-UHFFFAOYSA-N 0.000 description 1
- PQGJFNUTUBPGKE-UHFFFAOYSA-N C=1C=CC=CC=1C(=O)OBOC(=O)C1=CC=CC=C1 Chemical compound C=1C=CC=CC=1C(=O)OBOC(=O)C1=CC=CC=C1 PQGJFNUTUBPGKE-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19601745A DE19601745C1 (de) | 1996-01-19 | 1996-01-19 | Verfahren zur Racematspaltung von Tramadol |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| HU9700141D0 HU9700141D0 (en) | 1997-03-28 |
| HUP9700141A2 HUP9700141A2 (hu) | 1998-01-28 |
| HUP9700141A3 HUP9700141A3 (en) | 2000-03-28 |
| HU223067B1 true HU223067B1 (hu) | 2004-03-01 |
Family
ID=7783112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9700141A HU223067B1 (hu) | 1996-01-19 | 1997-01-16 | Eljárás tramadol racemáthasítására |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5723668A (enExample) |
| EP (1) | EP0787715B1 (enExample) |
| JP (1) | JPH09216858A (enExample) |
| KR (1) | KR100505527B1 (enExample) |
| CN (1) | CN1131203C (enExample) |
| AR (1) | AR005391A1 (enExample) |
| AT (1) | ATE189205T1 (enExample) |
| AU (1) | AU711750B2 (enExample) |
| BR (1) | BR9700094A (enExample) |
| CA (1) | CA2195370C (enExample) |
| CO (1) | CO4520185A1 (enExample) |
| CZ (1) | CZ291775B6 (enExample) |
| DE (2) | DE19601745C1 (enExample) |
| DK (1) | DK0787715T3 (enExample) |
| ES (1) | ES2145373T3 (enExample) |
| GR (1) | GR3032489T3 (enExample) |
| HU (1) | HU223067B1 (enExample) |
| IL (1) | IL120028A (enExample) |
| IN (1) | IN182218B (enExample) |
| MY (1) | MY116583A (enExample) |
| NO (1) | NO306059B1 (enExample) |
| NZ (1) | NZ299999A (enExample) |
| PE (1) | PE29898A1 (enExample) |
| PL (1) | PL187403B1 (enExample) |
| PT (1) | PT787715E (enExample) |
| RU (1) | RU2192407C2 (enExample) |
| SI (1) | SI0787715T1 (enExample) |
| SK (1) | SK281612B6 (enExample) |
| UA (1) | UA45343C2 (enExample) |
| UY (1) | UY24439A1 (enExample) |
| ZA (1) | ZA97369B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2130079B1 (es) * | 1997-07-10 | 2000-01-16 | Esteve Labor Dr | Resolucion de aminas |
| DE69809055T2 (de) * | 1997-07-15 | 2003-06-05 | Russinsky Ltd., Cork | Verfahren zur herstellung von reinem cis-tramadol |
| DE19821039A1 (de) * | 1998-05-11 | 1999-11-18 | Bayer Ag | Verfahren zur Herstellung von (S,S)-Benzyl-2,8-diazabicyclo[4.3.0]nonan |
| GB9826540D0 (en) | 1998-12-02 | 1999-01-27 | Darwin Discovery Ltd | Process |
| KR100342919B1 (ko) * | 1999-10-21 | 2002-07-04 | 박노중 | 트랜스체 염산 트라마돌의 분리 제조방법 |
| WO2002028383A1 (en) * | 2000-10-03 | 2002-04-11 | Penwest Pharmaceuticals Company | Delivery system for multi-pharmaceutical active materials at various release rates |
| DE10108122A1 (de) | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Arzneimittel auf Basis von Tramadol |
| NZ528935A (en) | 2001-03-16 | 2004-10-29 | Dmi Biosciences Inc | Method of delaying ejaculation |
| US6649783B2 (en) * | 2001-10-03 | 2003-11-18 | Euro-Celtique, S.A. | Synthesis of (+/-)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols |
| AU2002364517A1 (en) | 2001-11-30 | 2003-06-17 | Sepracor Inc. | Tramadol analogs and uses thereof |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| PL383715A1 (pl) | 2005-01-26 | 2008-05-12 | Allergan, Inc. | Amidy kwasu 3-arylo-3-hydroksy-2-amino-propionowego, amidy kwasu 3-heteroarylo-3-hydroksy-2-amino-propionowego i ich związki pokrewne posiadające aktywność przeciwbólową i/lub pobudzającą odporność |
| EP1785412A1 (en) | 2005-11-14 | 2007-05-16 | IPCA Laboratories Limited | Tramadol recovery process |
| US20080261991A1 (en) | 2007-02-12 | 2008-10-23 | Dmi Biosciences, Inc. | Reducing Side Effects of Tramadol |
| JP2010518167A (ja) | 2007-02-12 | 2010-05-27 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | 併存する早漏及び勃起障害の治療 |
| DE102013009114A1 (de) | 2013-05-29 | 2014-12-04 | Franz Gerstheimer | Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen |
| KR102136004B1 (ko) | 2018-06-18 | 2020-07-22 | (주)센텍코리아 | 감지부의 잔존 수명을 추정할 수 있는 음주측정기 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2528267A (en) * | 1950-10-31 | Eobeet j | ||
| US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
| IL50080A (en) * | 1975-07-29 | 1979-07-25 | Beecham Group Ltd | 4-oxa-1-azabicyclo(3.2.0)heptan-7-one-2-car boxylic acid derivatives and their preparation |
| GB9017390D0 (en) * | 1990-08-08 | 1990-09-19 | Norgine Ltd | Improvements in or relating to propylamine derivatives |
| JPH06122686A (ja) * | 1992-10-12 | 1994-05-06 | Fujisawa Pharmaceut Co Ltd | ラセミ体の光学分割法 |
-
1996
- 1996-01-19 DE DE19601745A patent/DE19601745C1/de not_active Expired - Fee Related
- 1996-11-22 MY MYPI96004865A patent/MY116583A/en unknown
- 1996-12-18 PE PE1996000930A patent/PE29898A1/es not_active Application Discontinuation
- 1996-12-21 DE DE59604295T patent/DE59604295D1/de not_active Expired - Lifetime
- 1996-12-21 AT AT96120726T patent/ATE189205T1/de active
- 1996-12-21 PT PT96120726T patent/PT787715E/pt unknown
- 1996-12-21 EP EP96120726A patent/EP0787715B1/de not_active Expired - Lifetime
- 1996-12-21 DK DK96120726T patent/DK0787715T3/da active
- 1996-12-21 SI SI9630150T patent/SI0787715T1/xx unknown
- 1996-12-21 ES ES96120726T patent/ES2145373T3/es not_active Expired - Lifetime
- 1996-12-23 NZ NZ299999A patent/NZ299999A/en not_active IP Right Cessation
- 1996-12-30 CO CO96068520A patent/CO4520185A1/es unknown
- 1996-12-31 US US08/775,396 patent/US5723668A/en not_active Expired - Lifetime
-
1997
- 1997-01-07 AR ARP970100069A patent/AR005391A1/es active IP Right Grant
- 1997-01-09 IN IN45CA1997 patent/IN182218B/en unknown
- 1997-01-10 UY UY24439A patent/UY24439A1/es not_active IP Right Cessation
- 1997-01-14 BR BR9700094A patent/BR9700094A/pt not_active Application Discontinuation
- 1997-01-16 HU HU9700141A patent/HU223067B1/hu not_active IP Right Cessation
- 1997-01-16 ZA ZA9700369A patent/ZA97369B/xx unknown
- 1997-01-17 AU AU12232/97A patent/AU711750B2/en not_active Ceased
- 1997-01-17 UA UA97010175A patent/UA45343C2/uk unknown
- 1997-01-17 CZ CZ1997156A patent/CZ291775B6/cs not_active IP Right Cessation
- 1997-01-17 CN CN97102069A patent/CN1131203C/zh not_active Expired - Fee Related
- 1997-01-17 KR KR1019970001203A patent/KR100505527B1/ko not_active Expired - Fee Related
- 1997-01-17 PL PL97318003A patent/PL187403B1/pl not_active IP Right Cessation
- 1997-01-17 IL IL12002897A patent/IL120028A/xx not_active IP Right Cessation
- 1997-01-17 JP JP9006903A patent/JPH09216858A/ja active Pending
- 1997-01-17 SK SK68-97A patent/SK281612B6/sk not_active IP Right Cessation
- 1997-01-17 NO NO970211A patent/NO306059B1/no not_active IP Right Cessation
- 1997-01-17 RU RU97100948/04A patent/RU2192407C2/ru not_active IP Right Cessation
- 1997-01-17 CA CA002195370A patent/CA2195370C/en not_active Expired - Fee Related
-
2000
- 2000-01-27 GR GR20000400183T patent/GR3032489T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2192407C2 (ru) | Способ расщепления рацематов трамадола | |
| EP2403823B1 (en) | Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process | |
| Kinbara et al. | Chiral discrimination upon crystallisation of the diastereomeric salts of 1-arylethylamines with mandelic acid or p-methoxymandelic acid: interpretation of the resolution efficiencies on the basis of the crystal structures | |
| US5728885A (en) | Method of preparing the enantiomers of O-dimethyltramadol | |
| JPH09216858A5 (enExample) | ||
| US8853456B2 (en) | Process for the preparation of tapentadol | |
| US20030092773A1 (en) | Process for the separation of the cis trans diasteroisomers of tramadol | |
| KR20070057703A (ko) | 거울상 이성체적으로 순수한 아토목세틴 및 토목세틴만델레이트 | |
| BRPI0614395A2 (pt) | método de obter carbamatos de fenila | |
| US9663456B2 (en) | Intermediate of tapentadol | |
| US7385080B2 (en) | Method for producing optically active β-phenylalanine compounds | |
| WO2007009405A1 (en) | A method for the preparation of (r)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine hydrochloride (atomoxetine) | |
| CN121358709A (zh) | 用于制备5-{2-[苄基-(1-(4-羟基苯基)-1-甲基乙基)氨基]-1-羟基乙基}苯-1,3-二醇半富马酸盐的方法 | |
| SK2072004A3 (sk) | Spôsob výroby N,N-diizopropyl-3-(2-hydroxy-5-metylfenyl)-3- fenylpropylamínu v jeho racemickej alebo opticky aktívnej forme | |
| EP0427904A1 (en) | A process for preparing R(+)-terodiline and salts thereof | |
| WO2021176381A1 (en) | A method for preparation of diastereomeric lactate salts of 1-(1-naphthyl)ethyl amine and pure enantiomers of 1-(1-naphthyl)ethyl amine | |
| CN101613292A (zh) | (s)-3-(1-二甲氨基乙基)苯酚的制备方法 | |
| MXPA97000483A (en) | Procedure for the optic resolution of ramatic blend mixtures | |
| WO2010032254A1 (en) | Industrial process for cis(+m-2-r(dimethylamino)-methyl-1-(3- methoxyphenyl) cyclohexanol hydrochloride | |
| WO2006046252A2 (en) | Novel diasteriomeric salts of atenolol and their use in the production of optically active atenolol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HFG4 | Patent granted, date of granting |
Effective date: 20040114 |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |